The “Tipping Point” : When Electroencephalography (EEG), Quantitative EEG (QEEG) and Standardized Low Resolution Brain Electromagnetic Tomography (sLORETA) in COVID Went From “Ceasure” To “Non- Priority” To “First-Line” Tool in Triage, Diagnosis, Monitoring and Therapy

Abstract

On the threshold of the COVID outbreak; electroencephalography (EEG) was used in diagnosis, crossborder disease differential diagnosis, disease-staging, monitoring of treatment, sedation and coma, in neuro-therapy and in declaration of brain death. EEG, quantitative EEG (QEEG), and standardized low resolution brain electromagnetic tomography (sLORETA) use entered the doldrums; reaching near “ceasure” due to COVID restrictions. Between 2020-2023, EEG use tipped, going from “Ceasure” to “First-Line” tool in triage, diagnosis, monitoring and therapy due to neurological, neurocognitive, neuropsychiatric, and neuromuscular sequelae of para- or acute- and post-COVID-19. The present paper will discuss this “Tipping point” in EEG, QEEG and sLORETA use.